We have located links that may give you full text access.
Achievement of glycemic control and antidepressant medication use in comorbid depression and type II diabetes.
Annals of Family Medicine 2022 April 2
Context: Limited previous work has suggested that treatment of co-morbid patients with anti-depressant medication (ADM) is associated with improved glycemic control.
Objective: To determine the association of ADM treatment on glycemic control at 3 time periods after diagnosis of diabetes.
Study Design: Retrospective cohort study.
Analysis: Propensity scores (PS) and inverse probability of treatment weighting (IPTW) controlled for confounding. Extended Cox models measured the association between adequate, inadequate vs. no treatment and glycemic control at 0 to 36 months, 36 to 72 months and ≥72 months.
Dataset: Optum®, a nationally distributed source dataset with a random sample of 5 million patients ≥18 years of age, from which we used de-identified data for 2011-2017.
Population Studied: Eligible patients aged 18-64 had type 2 diabetes (T2DM) with poor glycemic control, and diagnosis of depression at least one year prior to diagnosis of T2DM. Exclusion criteria included steroid use, HIV, cancer, and inadequate data. 7,332 patients meeting inclusion criteria were identified.
Intervention: ADM treatment (identified by patient prescriptions within the EHR) was defined as adequately treated (≥12 weeks of antidepressants), inadequately treated (<12 weeks) or untreated.
Outcome Measures: Glycemic control was defined as A1c<7.0%. Outcome was achievement of glycemic control at 0 to 36 months, 36 to 72 months and ≥72 months.
Results: After controlling for confounding, compared to no ADM treatment, adequate ADM treatment was significantly associated with achieving glycemic control within 36 months (HR 1.17, 95% CI 1.02-1.34). No association was observed beyond 36 months. There was no association between inadequate vs. no treatment and glycemic control.
Conclusions: Receipt of adequate ADM therapy is associated with achieving glycemic control in the first 3 years after a T2DM diagnoses with uncontrolled A1c.
Objective: To determine the association of ADM treatment on glycemic control at 3 time periods after diagnosis of diabetes.
Study Design: Retrospective cohort study.
Analysis: Propensity scores (PS) and inverse probability of treatment weighting (IPTW) controlled for confounding. Extended Cox models measured the association between adequate, inadequate vs. no treatment and glycemic control at 0 to 36 months, 36 to 72 months and ≥72 months.
Dataset: Optum®, a nationally distributed source dataset with a random sample of 5 million patients ≥18 years of age, from which we used de-identified data for 2011-2017.
Population Studied: Eligible patients aged 18-64 had type 2 diabetes (T2DM) with poor glycemic control, and diagnosis of depression at least one year prior to diagnosis of T2DM. Exclusion criteria included steroid use, HIV, cancer, and inadequate data. 7,332 patients meeting inclusion criteria were identified.
Intervention: ADM treatment (identified by patient prescriptions within the EHR) was defined as adequately treated (≥12 weeks of antidepressants), inadequately treated (<12 weeks) or untreated.
Outcome Measures: Glycemic control was defined as A1c<7.0%. Outcome was achievement of glycemic control at 0 to 36 months, 36 to 72 months and ≥72 months.
Results: After controlling for confounding, compared to no ADM treatment, adequate ADM treatment was significantly associated with achieving glycemic control within 36 months (HR 1.17, 95% CI 1.02-1.34). No association was observed beyond 36 months. There was no association between inadequate vs. no treatment and glycemic control.
Conclusions: Receipt of adequate ADM therapy is associated with achieving glycemic control in the first 3 years after a T2DM diagnoses with uncontrolled A1c.
Full text links
Related Resources
Trending Papers
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app